SK Biopharmaceuticals said on the 17th that its joint venture (JV) "Mentis Care" has begun joint research with Emory School of Medicine on an artificial intelligence (AI) model for seizure detection and real-time prediction.
The research aims to develop a "transformer-based EEG foundation model" that operates consistently across diverse settings, from hospital-grade multichannel electroencephalography (EEG) systems to reduced-channel wearable devices. The plan is to secure the technological basis for continuous epilepsy monitoring in everyday environments.
Mentis Care is a joint venture established in the United States by SK Biopharmaceuticals and the Latin American pharmaceutical company Eurofarma, and it is developing an AI-based platform for real-time seizure detection and prediction. The platform is in the form of software as a medical device (SaMD) and is currently pursuing authorization from the U.S. Food and Drug Administration (FDA).
Mentis Care will conduct the research using more than 1 million hours of de-identified EEG data held by Emory School of Medicine.
The research will proceed along five pillars: ▲ large-scale data curation and standardized preprocessing ▲ development of a seizure detection foundation model ▲ validation across diverse patient groups and recording environments ▲ model application to wearable EEG environments ▲ expansion to real-time pre-seizure prediction capabilities.
However, as this project is in its early stage, further research, clinical trials, and regulatory approval procedures will be required for eventual product development.
Hassan Kotob, Mentis Care chief executive officer (CEO), said, "This collaboration aims to secure the core technology that enables continuous, real-world monitoring."
Samaneh Nasiri, a doctor at Emory School of Medicine, said, "The foundation model has broad potential across healthcare," adding, "It will serve as an opportunity to expand the scope of EEG data use." Gari Clifford, chair of the Department of Biomedical Informatics at Emory, also said, "Through large-scale EEG analysis, we can contribute to research on a variety of diseases."
SK Biopharmaceuticals plans to enhance its EEG analysis AI technology and Wearable Device capabilities through this joint research. Lee Dong-hoon, SK Biopharmaceuticals president, said, "We will continue to drive patient-centered treatment innovation through AI-based Digital Healthcare."